Exploring the Relationship of Bone Turnover Markers and Bone Mineral Density in Community-Dwelling Postmenopausal Women

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2021 May 10

PMID 33968284

Citations 5

Authors

Xu Wei

Yili Zhang

Xinghua Xiang

Menghua Sun

Kai Sun

Tao Han

Baoyu Qi

Yanming Xie

Ranxing Zhang

LiGuo Zhu

Affiliations

Soon will be listed here.

Abstract

Aims: To explore the relationships of procollagen type 1 N-terminal propeptide (P1NP) and cross-linked C-telopeptide of type 1 collagen (-CTX) with bone mineral density (BMD) in postmenopausal women.

Methods: All postmenopausal women were selected from a community-based case-control study. The anteroposterior L1-L4 and left proximal femur BMD were measured. P1NP and -CTX were also collected and tested. The main correlation analysis was applied to explore the relationships of BMD, P1NP, and -CTX.

Results: The total 1055 postmenopausal women were enrolled. The BMD at all sites kept a decrease continually with age ( < 0.01). In addition, the level of -CTX increased significantly from 45 to 50 years old and remained at a high level in the later stage, while the level of P1NP changed little or even decreased with age. Logistic regression model showed that -CTX has better ability to predict BMD than P1NP, as demonstrated by an area under the curve (AUC) of 0.63.

Conclusion: P1NP and -CTX are important markers to monitor bone metabolism. This trial is registered with ChiCTR-SOC-17013090. The date of registration is Oct. 23, 2017.

Citing Articles

Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans.

Palmieri M, Maraka S, Spencer H, Thostenson J, Dishongh K, Knox M Sci Rep. 2025; 15(1):2109.

PMID: 39814831 PMC: 11735633. DOI: 10.1038/s41598-025-85624-9.

Regulation of bone homeostasis: signaling pathways and therapeutic targets.

Wu Z, Li W, Jiang K, Lin Z, Qian C, Wu M MedComm (2020). 2024; 5(8):e657.

PMID: 39049966 PMC: 11266958. DOI: 10.1002/mco2.657.

The prevalence and treatment of osteoporosis in patients undergoing total hip arthroplasty and the levels of biochemical markers of bone turnover.

Watanabe N, Miyatake K, Takada R, Ogawa T, Amano Y, Jinno T Bone Joint Res. 2022; 11(12):873-880.

PMID: 36464500 PMC: 9792872. DOI: 10.1302/2046-3758.1112.BJR-2022-0252.R1.

Risk of primary osteoporosis score (RPOPs): an algorithm model for primary osteoporosis risk assessment in grass-roots hospital.

Jiang X, Yan N, Zheng Y, Yang J, Zhao Y BMC Musculoskelet Disord. 2022; 23(1):1041.

PMID: 36456916 PMC: 9713074. DOI: 10.1186/s12891-022-06014-0.

Bone-turnover biomarkers as potential prognostic factors in sudden sensorineural hearing loss: A prospective cohort study.

Chen X, Zheng Z, Xiao L, Liu C, Shen Y, Ma N Front Neurol. 2022; 13:980150.

PMID: 36090873 PMC: 9453032. DOI: 10.3389/fneur.2022.980150.

References

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

Vasikaran S, Chubb S, Ebeling P, Jenkins N, Jones G, Kotowicz M . Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults. Clin Biochem Rev. 2015; 35(4):237-42. PMC: 4310062. View

Sun X, Yang X, Zhao Y, Li Y, Guo L . Effects of 17β-Estradiol on Mitophagy in the Murine MC3T3-E1 Osteoblast Cell Line is Mediated via G Protein-Coupled Estrogen Receptor and the ERK1/2 Signaling Pathway. Med Sci Monit. 2018; 24:903-911. PMC: 5819311. DOI: 10.12659/msm.908705. View

Awasthi H, Mani D, Singh D, Gupta A . The underlying pathophysiology and therapeutic approaches for osteoporosis. Med Res Rev. 2018; 38(6):2024-2057. DOI: 10.1002/med.21504. View

Cong Q, Jia H, Biswas S, Li P, Qiu S, Deng Q . p38α MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions. Stem Cell Reports. 2016; 6(4):566-578. PMC: 4834033. DOI: 10.1016/j.stemcr.2016.02.001. View

Nishizawa Y, Ohta H, Miura M, Inaba M, Ichimura S, Shiraki M . Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab. 2012; 31(1):1-15. DOI: 10.1007/s00774-012-0392-y. View

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K . Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130(5):811-23. DOI: 10.1016/j.cell.2007.07.025. View

Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris H, Trenti T . International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011; 49(8):1271-1274. DOI: 10.1515/CCLM.2011.602. View

Koivula M, Risteli L, Risteli J . Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem. 2012; 45(12):920-7. DOI: 10.1016/j.clinbiochem.2012.03.023. View

10.

Zhao J, Xia W, Nie M, Zheng X, Wang Q, Wang X . The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study. Menopause. 2011; 18(11):1237-43. DOI: 10.1097/gme.0b013e31821d7ff7. View

11.

Gossiel F, Altaher H, Reid D, Roux C, Felsenberg D, Gluer C . Bone turnover markers after the menopause: T-score approach. Bone. 2018; 111:44-48. DOI: 10.1016/j.bone.2018.03.016. View

12.

Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P . National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012; 23(10):2425-33. PMC: 4011662. DOI: 10.1007/s00198-012-2049-z. View

13.

Filip R, Zagorski J . Age- and BMD-related differences in biochemical markers of bone metabolism in rural and urban women from Lublin Region, Poland. Ann Agric Environ Med. 2005; 11(2):255-9. View

14.

Fujiwara Y, Piemontese M, Liu Y, Thostenson J, Xiong J, OBrien C . RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice. J Biol Chem. 2016; 291(48):24838-24850. PMC: 5122756. DOI: 10.1074/jbc.M116.742452. View

15.

Lou H, Peng C, Chen Q . [Clinical value of serum total P1NP, β-CTX and 25(OH)D3 detection in evaluating risks of fragile hip fracture in elderly patients with osteoporosis]. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32(9):1346-9. View

16.

Seibel M . Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2006; 26(4):97-122. PMC: 1320175. View

17.

Hu W, Zhang Z, He J, Fu W, Wang C, Zhang H . Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women. Int J Endocrinol. 2013; 2013:513925. PMC: 3600195. DOI: 10.1155/2013/513925. View

18.

Gao C, Xu Y, Li L, Gu W, Yi C, Zhu Q . Prevalence of osteoporotic vertebral fracture among community-dwelling elderly in Shanghai. Chin Med J (Engl). 2019; 132(14):1749-1751. PMC: 6759100. DOI: 10.1097/CM9.0000000000000332. View

19.

Yan G, Huang Y, Cao H, Wu J, Jiang N, Cao X . Association of breastfeeding and postmenopausal osteoporosis in Chinese women: a community-based retrospective study. BMC Womens Health. 2019; 19(1):110. PMC: 6692954. DOI: 10.1186/s12905-019-0808-0. View

20.

Adami S, Bianchi G, Brandi M, Giannini S, Ortolani S, DiMunno O . Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int. 2008; 82(5):341-7. DOI: 10.1007/s00223-008-9126-5. View